Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen.

Vaccine - 12 Jul 2010

O'Neilla Ciaragh, Jones Sophie C P, Bossé Janine T, Watson Conrad M, Williamson Susanna M, Rycroft Andrew N, Simon Kroll J, Hartley Helen M, Langford Paul R

Abstract excerpt

APXIVA is an RTX toxin of Actinobacillus pleuropneumoniae that is a candidate antigen to differentiate infected from vaccinated animals (DIVA). Insertion of ISApl1 into the apxIVA gene is known to compromise an APXIVA-based DIVA approach, as is potentially a TGG to TGA mutation in the apxIVA gene. ISApl1 was found in 63/349 (18.1%) A. pleuropneumoniae isolates from England and Wales including serovars 2, 3, 6-8...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to England
Share to Actinobacillus Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Actinobacillus pleuropneumoniae

Share to Antigens, Bacterial

Share to Bacterial Proteins

Share to DNA, Bacterial

Share to Mutagenesis, Insertional

Source

Open in PubMed Open full text

Identifiers

PMID: 20483193
DOI: 10.1016/j.vaccine.2010.04.113
PMCID: PMC4843962

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen.PMID 20483193Read ↗

Characterization of apxlVA, a new RTX determinant of Actinobacillus pleuropneumoniaeSemantic proximity Read ↗

Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.Semantic proximity Read ↗

New trends in innovative vaccine development against Actinobacillus pleuropneumoniae.Semantic proximity Read ↗

Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals.Semantic proximity Read ↗

Development and use of a multiplex polymerase chain reaction assay based on Apx toxin genes for genotyping of Actinobacillus pleuropneumoniae isolates.Semantic proximity Read ↗

Sero- and apx-typing of German Actinobacillus pleuropneumoniae field isolates from 2010 to 2019 reveals a predominance of serovar 2 with regular apx-profile.Semantic proximity Read ↗

Comparison of molecular serotyping methods for Actinobacillus pleuropneumoniae and analysis of atypical serotypes detected in routine diagnosticsSemantic proximity Read ↗

Genotypic prevalence of apx1V in Actinobacillus pleuropneumoniae field isolates.Semantic proximity Read ↗

An Actinobacillus pleuropneumoniae PCR typing system based on the apx and omlA genes — evaluation of isolates from lungs and tonsils of pigsSemantic proximity Read ↗

Virulence in Actinobacillus pleuropneumoniae and RTX toxins.Semantic proximity Read ↗

Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.Semantic proximity Read ↗

A new variant of Actinobacillus pleuropneumoniae serotype 3 lacking the entire apxII operon.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.